Calypte Biomedical Corp. Earnings Conference Call (Q3 2003)
Scheduled to start Mon, Nov 17, 2003, 12:00 pm Eastern
Calypte Biomedical Corporation develops, manufactures and markets urine-based screening and supplemental tests for the detection of antibodies to the Human Immunodeficiency Virus, Type-1 (HIV-1), the putative cause of Acquired Immunodeficiency Syndrome (AIDS). It has obtained United States Food and Drug Administration (FDA) approval for the marketing and sale of urine-based tests for the detection of antibodies to the HIV-1. In clinical trials using the screening and supplemental tests together, the urine HIV antibody testing algorithm detected the presence of HIV antibodies in urine with 99.7% sensitivity in subjects previously identified as HIV-1 infected through blood-based (serum/plasma) screening tests.
More from Multex: Expanded Business Description |
Thread abonnieren
